Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | Phase 4 | 101 | AmgenINDUSTRY | 1 | May 11, 2026 |
| clinicaltrials |
| NCT02844309 | The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM(BDH-WM02) | completed | Phase 4 | 44 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02844322 | The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia(BDH-WM01) | completed | Phase 4 | 35 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02844361 | Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia(BDH-WM03) | completed | Phase 4 | 70 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02858804 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL(BDH-MCL01) | completed | Phase 4 | 55 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | completed | Phase 4 | 20 | Thomas Jefferson UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | completed | Phase 4 | 10 | TakedaINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04042376 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | completed | Phase 4 | 17 | Janssen Research & Development, LLCINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04217967 | Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | completed | Phase 4 | 211 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT00733538 | Stage I Multiple Myeloma Treatment(IFM-01-04) | completed | Phase 4 | 89 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT01088750 | Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma(EuroNetLP1) | completed | Phase 4 | 225 | Christine Mauz-KörholzOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00168727 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | completed | Phase 4 | 12 | BiogenINDUSTRY | 1 | Aug 23, 2023 | clinicaltrials |
| NCT02286830 | Prolonged Protection From Bone Disease in Multiple Myeloma(Magnolia) | completed | Phase 4 | 158 | Thomas LundOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03619252 | Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents | completed | Phase 4 | 36 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00199082 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | completed | Phase 4 | 650 | Nicola GoekbugetOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04349306 | Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia(RAISE) | completed | Phase 4 | 50 | SanofiINDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT00622505 | Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants(Z-MARK) | completed | Phase 4 | 121 | Novartis PharmaceuticalsINDUSTRY | 1 | May 26, 2021 | clinicaltrials |
| NCT01990534 | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 4 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 9, 2021 | clinicaltrials |
| NCT01087008 | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse(AZABACHE) | completed | Phase 4 | 103 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01731886 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | completed | Phase 4 | 60 | Columbia UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02958969 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | completed | Phase 4 | 50 | Gregory PiazzaOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00003398 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 4 | 45 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT03376958 | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | completed | Phase 4 | 32 | Zhengzhou UniversityOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
| NCT02095951 | Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection | completed | Phase 4 | 30 | Children's Hospital of MichiganOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03226119 | MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study | completed | Phase 4 | 150 | MP Biomedicals, LLCINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00221039 | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | completed | Phase 4 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | completed | Phase 4 | 545 | Hoffmann-La RocheINDUSTRY | 24 | Aug 14, 2017 | clinicaltrials |
| NCT01569724 | Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma(TgBEX) | completed | Phase 4 | 10 | Rennes University HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02782845 | An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 4 | 53 | Hoffmann-La RocheINDUSTRY | 2 | Nov 21, 2016 | clinicaltrials |
| NCT01664975 | Treatment of Peripheral T-cell Lymphoma | completed | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT02268890 | A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | completed | Phase 4 | 18 | Johnson & Johnson Taiwan LtdINDUSTRY | 1 | Jul 11, 2016 | clinicaltrials |
| NCT02805218 | PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy | completed | Phase 4 | 410 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 20, 2016 | clinicaltrials |
| NCT01658280 | Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies | completed | Phase 4 | 253 | Azienda Ospedaliero, Universitaria Ospedali RiunitiOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT00352703 | PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation | completed | Phase 4 | 145 | Swedish Orphan BiovitrumINDUSTRY | 0 | Nov 3, 2014 | clinicaltrials |
| NCT00808171 | Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture | completed | Phase 4 | 52 | Federal University of Minas GeraisOTHER | 1 | Jul 29, 2014 | clinicaltrials |
| NCT01164475 | Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms | completed | Phase 4 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials